Kentucky Network for Innovation & Commercialization (“KYNETIC”)

肯塔基州创新网络

• 批准号: 10475211
• 负责人: Linda P Dwoskin
• 金额: $ 95.82万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-23 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10475211
• 关键词: Address; Area; Back; Biomedical Research; Businesses; Clinic; Collaborations; Complement 3a; Development; Devices; Diagnostic tests; Economic Development; Economics; Ecosystem; Education; Entrepreneurship; Evaluation Research; Federal Government; Fund Raising; Funding; Goals; Grant; Health; Health Benefit; Human; Individual; Industry; Institution; Kentucky; Knowledge; Laboratories; Leadership; Licensing; Medical Device; Mentors; Mission; Modeling; Paper; Pharmacologic Substance; Principal Investigator; Private Sector; Privatization; Process; Publishing; Research; Resources; Risk; Services; Site; Source; State Government; Structure; System; Technology; Technology Transfer; Text; Translational Research; Translations; Underrepresented Populations; United States; United States National Institutes of Health; Universities; Work; biomedical resource; college; commercialization; community college; experience; health disparity; improved; industry partner; innovation; interest; member; novel therapeutics; programs; public-private partnership; role model; skill acquisition; synergism; technical college; tool

ABSTRACT Knowledge generated by academic research is a major source of health-related innovations. Transforming innovative discoveries into commercialized products that improve human health is a difficult process. However, all stakeholders (universities, funding bodies, pharmaceutical and medical device industries, federal and state governments and the public) have a vested interest in identifying scalable approaches that accelerate the translation of academic innovations into biomedical products. The goal of the Kentucky Network for Innovation and Commercialization (KYNETIC) is to build a Research Evaluation and Commercialization Hub (REACH) network of commercialization resources accessible across the entire Commonwealth of Kentucky to accelerate translation of academic innovations into biomedical products. To reach this goal, the following aims will be conducted: 1) establish KYNETIC’s organizational and collaborative structure; 2) Find, fund and manage product definition/development projects; 3) Provide mentoring, skills development, experiential education and networking opportunities with industry experts, entrepreneurs and investors; and 4) Devise and implement a plan to transition to a self-sustaining entity. KYNETIC will build on lessons learned from developing a regional IDeA technology transfer accelerator (at UK) and a current REACH hub (at UL). KYNETIC will be led by the University of Kentucky (UK), in partnership with the University of Louisville (UL) and the Commonwealth Commercialization Center (C3), a private 501(c)3 non-profit commercialization organization. Also, KYNETIC will include all of Kentucky’s public regional universities and community and technical college system (KCTCS). KYNETIC’s mission is to nurture innovations and academic innovators by providing funding, mentoring, education and a network of relevant expertise. Required matching funds for KYNETIC have been committed in full by Kentucky Commonwealth Economic Development (CED) and the state R1 universities. KYNETIC will be directed by a leadership team consisting of 2 academic innovators, 2 technology transfer professionals (from UK and UL) and 2 representatives from partnering entities (C3 and CED). A steering committee including the leadership team and representatives from each participating institution, an External Review Board and the NIH will review and evaluate KYNETIC projects and fund up to 13 projects/yr using an innovative “quick kill” management strategy. Our services will be available to as many individuals as possible. Diverse role models including innovators and entrepreneurs from underrepresented groups will be sought. The proposed Kentucky-wide REACH program will leverage our collective wealth of resources, ecosystems and extensive experience to apply and expand best practices for innovator education and mentoring. The overall impact of KYNETIC will be unprecedented opportunities for collaboration and synergy, well-prepared innovators, a statewide pro-entrepreneurial culture and delivery of de-risked technologies to benefit health and overcome the state’s health disparities.

摘要 学术研究所产生的知识是与卫生有关的创新的主要来源。转化 将创新发现转化为改善人类健康的商业化产品是一个艰难的过程。但是，在这方面， 所有利益相关者（大学、资助机构、制药和医疗器械行业、联邦和州 政府和公众）在确定可扩展的方法以加速 将学术创新转化为生物医学产品。肯塔基州创新网络的目标是 研究评估和商业化中心（Research Evaluation and Commercialization Hub，REACH） 在整个肯塔基州联邦可访问的商业化资源网络，以加速 将学术创新转化为生物医学产品。为实现这一目标，将实现以下目标： 进行：1）建立KYNETIC的组织和协作结构; 2）寻找，资助和管理产品 定义/发展项目; 3）提供指导、技能发展、体验式教育和网络 与行业专家，企业家和投资者的机会;以及4）制定和实施计划， 向自我维持的实体过渡。KYNETIC将借鉴开发区域IDEA的经验教训 技术转移加速器（在英国）和当前的REACH中心（在UL）。KYNETIC将由大学领导 肯塔基州（英国），与路易斯维尔大学（UL）和英联邦商业化 中心（C3），一个私人501（c）3非营利性商业化组织。此外，KYNETIC将包括所有 肯塔基州的公立区域大学和社区技术学院系统（KCTCS）。KYNETIC的 使命是通过提供资金、指导、教育和 相关专业知识网络。肯塔基州已全额承诺为KYNETIC提供所需的配套资金 联邦经济发展（CED）和州立R1大学。Kynetic将由一位 领导团队由2名学术创新者，2名技术转移专业人员（来自英国和UL）和 2名伙伴实体代表（C3和CED）。包括领导团队在内的指导委员会 和来自每个参与机构的代表，外部审查委员会和NIH将审查和 使用创新的“快速终止”管理策略评估KYNETIC项目并每年资助多达13个项目。 我们的服务将提供给尽可能多的人。包括创新者在内的各种榜样， 将寻找代表性不足群体的企业家。拟议中的剑桥范围的REACH计划将 利用我们的集体资源、生态系统和丰富经验，以最佳方式应用和扩展 创新者教育和指导的实践。KYNETIC的整体影响将是前所未有的 合作和协同作用的机会，准备充分的创新者，全州范围内的亲创业文化 提供降低风险的技术，以造福健康，克服国家的健康差距。

项目成果

Analgesic effects of a highly selective mPGES-1 inhibitor.

• DOI: 10.1038/s41598-023-30164-3
• 发表时间: 2023-02-27
• 期刊: SCIENTIFIC REPORTS
• 影响因子: 4.6
• 作者: Stewart, Madeline J.;Weaver, Lauren M.;Ding, Kai;Kyomuhangi, Annet;Loftin, Charles D.;Zheng, Fang;Zhan, Chang-Guo
• 通讯作者: Zhan, Chang-Guo